Novo Nordisk (NOVOB DC), at its shareholder meeting, said pricing headwinds are the primary near-term drag, ex-US semaglutide loss-of-exclusivity is also putting downward pressure on prices with the net effect of volume growth but revenue compression

Novo Nordisk's announcement highlights significant pricing pressures on its products, particularly due to loss of exclusivity for semaglutide in markets outside the U.S. This suggests potential underperformance in revenue growth despite volume increases, which could influence market sentiment and weigh on the stock, especially amid broader sector dynamics.